Guidance, NICE advice and quality standards In development

Skip to filtersSkip to results

Skip to results

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 11 to 20 of 374

TitleTypeExpected publication date
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years (MA review of TA554) [ID6290]Technology appraisal guidance
Selinexor with bortezomib and low-dose dexamethasone for treating relapsed refractory multiple myeloma [ID3797]Technology appraisal guidance
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy [ID3935]Technology appraisal guidance
Selective internal radiation therapy (SIRT) for neuroendocrine tumours metastatic to the liverInterventional procedures guidance
Endoscopic duodenal mucosal resurfacing for type 2 diabetesInterventional procedures guidance
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome [ID3947]Technology appraisal guidance
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]Technology appraisal guidance
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over [ID5104]Technology appraisal guidance
Harmful gambling: identification, assessment and managementNICE guideline
Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation [ID6198]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All